Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
AstraZeneca PLC (AZN.ST)
Cambridge, GB
AstraZeneca PLC functions as a global biopharmaceutical enterprise, dedicated to the entire lifecycle of prescription medicines, from initial discovery and development through manufacturing and commercialization. Its extensive product portfolio targets a broad spectrum of therapeutic areas. In oncology, key marketed treatments include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism conditions, the company offers medicines such as Brilinta/Brilique, Bydureon/Byetta, BCise, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology products comprise Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Rare disease therapies feature Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. Beyond these core categories, AstraZeneca also markets Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza prevention; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; gastrointestinal treatments Nexium and Losec/Prilosec; and COVID-19 related solutions Vaxzevria and Evusheld. AstraZeneca serves healthcare professionals in both primary and specialty care settings. It leverages a robust distribution network and local representative offices to reach markets across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The company frequently engages in strategic collaboration agreements to advance its pipeline. Notable partnerships include those with Regeneron Pharmaceuticals, Inc. for researching, developing, and commercializing small molecule medicines targeting obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy currently in Phase III trials for transthyretin amyloidosis; Proteros Biostructures GmbH for joint discovery of novel small molecules aimed at hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Incorporated in 1992, the company initially operated as Zeneca Group PLC before adopting its current name, AstraZeneca PLC, in April 1999. Its corporate headquarters are situated in Cambridge, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.73% | +3.42% | -6.61% | -5.34% | +4.01% | +2.51% | +31.35% | +11.56% | +87.85% | +266.97% | +399.71% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | +1 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%+8.6% ★ Q1'26: +12.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+45.3% ★ Q1'26: +5.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+15.5% ★ Q1'26: +11.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+24.0% ★ Q1'26: +28.2% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+16.0% ★ Q1'26: +18.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%-0.1% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×1.49× Q1'26: 1.49× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 22 Rev. Ana. 6 EPS Ana. |
Dec 2027 22 Rev. Ana. 5 EPS Ana. |
Dec 2028 10 Rev. Ana. 2 EPS Ana. |
Dec 2029 15 Rev. Ana. 1 EPS Ana. |
Dec 2030 11 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
24.71B
est: 24.31B (+1.6%)
|
23.00B
est: 22.56B (+2.0%)
|
22.47B
est: 21.55B (+4.2%)
|
22.09B
est: 23.50B (-6.0%)
|
24.38B
est: 25.03B (-2.6%)
|
26.62B
est: 26.29B (+1.2%)
|
37.42B
est: 36.47B (+2.6%)
|
44.35B
est: 45.43B (-2.4%)
|
45.81B
est: 4.65B (+885.5%)
|
54.07B
est: 53.12B (+1.8%)
|
58.74B
est: 58.65B (+0.2%)
|
62.11B
60.62B – 63.50B
+5.9% YoY
|
66.43B
59.85B – 69.80B
+7.0% YoY
|
70.73B
66.30B – 73.35B
+6.5% YoY
|
76.27B
71.49B – 79.09B
+7.8% YoY
|
81.46B
76.36B – 84.48B
+6.8% YoY
|
| EBITDA |
6.96B
est: 5.95B (+16.9%)
|
7.28B
est: 5.53B (+31.7%)
|
6.62B
est: 5.28B (+25.5%)
|
7.11B
est: 5.76B (+23.6%)
|
6.71B
est: 6.13B (+9.5%)
|
8.08B
est: 6.44B (+25.5%)
|
5.11B
est: 8.93B (-42.7%)
|
9.09B
est: 11.13B (-18.3%)
|
13.46B
est: 2.41B (+458.7%)
|
15.44B
est: 27.53B (-43.9%)
|
19.83B
est: 30.39B (-34.8%)
|
32.19B
31.41B – 32.90B
+5.9% YoY
|
34.42B
31.01B – 36.17B
+7.0% YoY
|
36.66B
34.36B – 38.01B
+6.5% YoY
|
39.52B
37.05B – 40.99B
+7.8% YoY
|
42.22B
39.57B – 43.78B
+6.8% YoY
|
| EBIT |
4.11B
est: 3.34B (+23.1%)
|
4.92B
est: 3.10B (+58.9%)
|
3.59B
est: 2.96B (+21.3%)
|
3.36B
est: 3.23B (+4.1%)
|
2.95B
est: 3.44B (-14.1%)
|
5.19B
est: 3.61B (+43.8%)
|
1.01B
est: 5.00B (-79.8%)
|
3.83B
est: 6.24B (-38.6%)
|
8.53B
est: 2.05B (+315.3%)
|
10.37B
est: 23.46B (-55.8%)
|
14.10B
est: 25.90B (-45.6%)
|
27.43B
26.77B – 28.04B
+5.9% YoY
|
29.34B
26.43B – 30.83B
+7.0% YoY
|
31.24B
29.28B – 32.39B
+6.5% YoY
|
33.68B
31.57B – 34.93B
+7.8% YoY
|
35.98B
33.72B – 37.31B
+6.8% YoY
|
| Net Income |
2.83B
est: 6.61B (-57.3%)
|
3.50B
est: 6.52B (-46.4%)
|
3.00B
est: 5.79B (-48.2%)
|
2.16B
est: 5.65B (-61.8%)
|
1.34B
est: 5.76B (-76.8%)
|
3.20B
est: 6.52B (-50.9%)
|
112.00M
est: 8.11B (-98.6%)
|
3.29B
est: 10.73B (-69.4%)
|
5.96B
est: 609.29M (+877.4%)
|
7.04B
est: 12.61B (-44.2%)
|
10.23B
est: 14.31B (-28.5%)
|
15.65B
15.43B – 15.86B
+9.4% YoY
|
17.71B
17.47B – 17.96B
+13.2% YoY
|
19.79B
18.18B – 20.74B
+11.7% YoY
|
22.68B
20.83B – 23.77B
+14.6% YoY
|
25.32B
23.26B – 26.54B
+11.7% YoY
|
| SGA |
11.02B
est: 10.03B (+9.9%)
|
9.74B
est: 9.31B (+4.6%)
|
10.54B
est: 8.89B (+18.5%)
|
10.36B
est: 9.70B (+6.8%)
|
11.44B
est: 10.33B (+10.7%)
|
11.69B
est: 10.85B (+7.8%)
|
15.68B
est: 15.05B (+4.2%)
|
18.96B
est: 18.75B (+1.1%)
|
18.22B
est: 1.83B (+893.3%)
|
20.53B
est: 20.96B (-2.0%)
|
20.51B
est: 23.14B (-11.4%)
|
24.51B
23.92B – 25.06B
+5.9% YoY
|
26.21B
23.62B – 27.55B
+7.0% YoY
|
27.91B
26.16B – 28.95B
+6.5% YoY
|
30.10B
28.21B – 31.21B
+7.8% YoY
|
32.15B
30.13B – 33.34B
+6.8% YoY
|
| EPS |
2.23
est: 4.23 (-47.3%)
|
2.77
est: 4.17 (-33.6%)
|
2.37
est: 3.71 (-36.0%)
|
1.70
est: 3.61 (-52.9%)
|
1.03
est: 3.69 (-72.1%)
|
2.44
est: 4.17 (-41.5%)
|
0.08
est: 5.19 (-98.5%)
|
2.12
est: 6.87 (-69.1%)
|
3.81
est: 0.39 (+868.6%)
|
4.54
est: 8.21 (-44.7%)
|
6.60
est: 9.16 (-27.9%)
|
10.04
9.88 – 10.15
+9.6% YoY
|
11.37
11.18 – 11.50
+13.2% YoY
|
12.67
11.64 – 13.28
+11.4% YoY
|
14.52
13.34 – 15.22
+14.6% YoY
|
16.21
14.89 – 16.99
+11.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Pascal Claude Roland Soriot | Chief Executive Officer & Executive Director | 6M | male |
| Aradhana Sarin | Chief Financial Officer & Executive Director | 3M | — |
| Clive Green | Head of Global Sample Management & Discovery Sciences - R&D and Executive Director | — | male |
| David Fredrickson | Executive Vice-President of Oncology Haematology Business Unit | — | male |
| Elisabeth Bjork | Senior VP of Late-Stage Development, Cardiovascular, Renal & Metabolism - BioPharmaceuticals R&D | — | — |
| Iskra Reic | Executive Vice President of International | — | female |
| Jeffrey Pott | CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board | — | male |
| Jim Weatherall | Chief Data Scientist of BioPharmaceuticals R&D | — | male |
| Joris Silon | Head of Investor Relations | — | male |
| Lutz Jermutus | Head of Projects | — | male |
| Pam Cheng | EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board | — | female |
| Regina Fritsche-Danielson | SVP and Head of Research & Early Dev., Cardiovascular, Renal & Metabolism - BioPharmaceuticals R&D | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AZN.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
